- Previous Close
29.75 - Open
30.60 - Bid 29.95 x 3600
- Ask 30.30 x 6200
- Day's Range
29.80 - 30.60 - 52 Week Range
26.05 - 48.60 - Volume
887 - Avg. Volume
5,857 - Market Cap (intraday)
368.324M - Beta (5Y Monthly) 0.23
- PE Ratio (TTM)
36.95 - EPS (TTM)
0.82 - Earnings Date Oct 25, 2024
- Forward Dividend & Yield 0.55 (1.85%)
- Ex-Dividend Date May 20, 2024
- 1y Target Est
41.00
Stratec SE, together with its subsidiaries, designs and manufactures automation and instrumentation solutions in the fields of in-vitro diagnostics and life sciences in Germany, European Union, and internationally. It designs and manufactures automated analyzer systems for clinical diagnostics and biotechnology customers; and offers complex consumables for diagnostics and medical applications. The company was formerly known as STRATEC Biomedical AG and changed its name to Stratec SE in December 2018. Stratec SE was founded in 1979 and is headquartered in Birkenfeld, Germany.
www.stratec.comRecent News: SBS.DE
View MorePerformance Overview: SBS.DE
Trailing total returns as of 1/6/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SBS.DE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SBS.DE
View MoreValuation Measures
Market Cap
361.64M
Enterprise Value
468.80M
Trailing P/E
36.28
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.44
Price/Book (mrq)
1.59
Enterprise Value/Revenue
1.87
Enterprise Value/EBITDA
12.29
Financial Highlights
Profitability and Income Statement
Profit Margin
4.00%
Return on Assets (ttm)
3.13%
Return on Equity (ttm)
4.41%
Revenue (ttm)
250.54M
Net Income Avi to Common (ttm)
10.01M
Diluted EPS (ttm)
0.82
Balance Sheet and Cash Flow
Total Cash (mrq)
33.11M
Total Debt/Equity (mrq)
66.97%
Levered Free Cash Flow (ttm)
-48.1M